Drug Delivery Systems

Drug delivery systems have come a long way since the days of traditional dosage forms, which are often limited regarding targeted delivery, low efficacy, and unwanted side effects. Converting potent drugs into effective therapies requires suitable carrier systems, increasing the stability of drug molecules, enabling administration to the human body, and improving specific targeting of cells and tissues. Our team works on innovative nanoscale drug delivery systems as well as novel and creative approaches to optimize local drug delivery. Both have the potential to revolutionize the way drugs are administered and ultimately improve patient treatment.

Vesicles & Particles

The targeted delivery of pharmaceutical actives to their intended site of action poses a major challenge in the establishment of new therapeutic strategies. Nanocarriers hold great potential to make drug delivery more efficient by providing a transport system, protective shield, and customizable surface to evade or specifically target different cells of the body. We are working on developing adaptive nanocarriers, based on natural or (semi-)synthetic polymers, carbohydrates, or lipids, to safely deliver cargo such as small molecules, PROTACS, RNA or proteins.

CDC6 45s Sput04

Related Publications

Associated Team Members


Electrospun Fibers

The task of delivering fragile drug molecules locally to skin and mucosa is a significant challenge in the field of pharmaceutical research. To combat this issue, we develop nanofibrous delivery systems for the controlled release of small molecules and biomacromolecules. By using Electrospinning, a technique utilizing high voltage to generate ultrafine polymer fibers, we design tailor-made systems that offer controllable release kinetics. Additionally, we are able to context-specifically adapt the mucoadhesive, antimicrobial, or regenerative properties of the generated fiber mats/scaffolds.

Associated Team Members


With our innovativenanocarrier platforms, we’re particularly interested in the delivery of small molecules, PROTACS, RNA, and proteins. These active pharmaceutical ingredients (APIs) have unique properties that make them attractive therapeutics: Small molecules can be used to target specific pathways within cells, while PROTACS enable targeted protein degradation. RNA and proteins are essential building blocks of the body, and their delivery can help treat a wide range of diseases.

Our research into nanocarrier-based drug delivery systems for those APIs is essential to improve the efficiency and safety of next generation therapeutics.